

EUROPEAN MEDECINES AGENCY

Paris, 25th July 2019

Dear Président of EMA,  
Dear membres of EMA,

The AFLAR Patient Association, which supports patients in France with osteoporosis, wishes to express its hope for Romosozumab.  
Osteoporosis is insufficiently diagnosed and inadequately treated. French patients have high hopes for the research and treatment of osteoporosis.

The new treatments improve the therapeutic strategy and allow to hope a better adhesion to the treatment of the osteoporosis and a better tolerance as well as a better observance.

We wish as an association of patients to bring you our point of view and are waiting for a positive response.  
Romosozumab has been accepted for use in patients with osteoporosis, Canada, Korea, Japan, USA.

We are looking forward to your decision.  
We thank you for your attention on this important topic in osteoporosis.

If you please, let us know your position so important for patients suffering from osteoporosis.

Best regards

Laurent Grange,  
CARTON,  
Président  
Générale

Françoise ALLIOT-LAUNOIS,  
Vice-Présidente

Gérard CHALÈS,  
Trésorier

Laurence  
Secrétaire

